Psychedelic Alpha’s Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, Vice President Psychiatry Development at Neurocrine Biosciences. For the purposes of this conversation, however, we focus on
Last month, psychedelic drug developer MindMed scored an FDA breakthrough therapy designation for its LSD-D-tartrate candidate (MM120) in the treatment of generalised anxiety disorder (GAD). The company
The real substance of the meeting consisted of Board members reviewing public feedback received in DORA’s Stakeholder Engagement Meeting. Unfortunately, the nature of the current
Josh Hardman, Psychedelic Alpha: The Bill references “any form of psilocybin or methylenedioxymethamphetamine that is in federal Food and Drug Administration Phase 3 testing for
PSYCHEDELIC DRUG DEVELOPMENT NEWS Drug Developer Skips the Trip Entirely, Unveils Deuterium-Assisted Psychotherapy Candidate (Apr 1) Initial reports describe the experience, though lacking psychedelics’ characteristic
In this issue of the Psychedelic Patent Analysis, we look at IP and exclusivity in MDMA drug development across Lykos, atai, MindMed, Arcadia, and PharmAla. We
Featured content in this Issue: A Look at Potential Mutual Recognition of FDA Approval for Psychedelics Via the UK MHRA’s International Recognition Procedure Beckley Psytech
Yesterday, the Institute for Clinical and Economic Review (ICER) published its draft evidence report on MDMA-assisted psychotherapy (which it abbreviates to ‘MDMA-AP’) for the treatment of PTSD. ICER
This Issue contains three SXSW-inspired musings or updates. The first, and most substantial, looks ahead to just one facet of the potential patient access challenges
Pre-clinical/Basic Sciences To start off the conference, Dr. Kevin Murnane, Associate Professor at Louisiana State University (LSU) Health Sciences Center Shreveport, presented parallel research on